Survodutide

Survodutide is a dual GLP-1 and glucagon receptor agonist primarily utilized for weight loss, appetite suppression, and the management of MASH or NASH. Users typically run daily subcutaneous doses ranging from 300 µg to 10 mg, with clinician-tier protocols centering on 6 mg daily. While reports of nausea and sleep disturbances occasionally surface, the primary tradeoff for the user is that the off-label evidence base remains significantly thinner than the current discourse suggests, as most exploratory indications lack published results. Injection-site reactions and fluid retention have not been consistent themes in community reports.

Half-life~7 days

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsAnecdotalEfficacyAnecdotalSideEffectsPrice3.63.52.33.43.32.0

Research Evidence

Evidence shape

Survodutide holds moderate clinical evidence, primarily supported by trials targeting obesity, non-alcoholic steatohepatitis, and type 2 diabetes. While the research includes phase 3 data and 21 registered trials, only three of the nine mapped indications currently have posted results, leaving the majority of the clinical program in thin or exploratory stages. The evidence base remains concentrated in a small number of completed studies, with significant portions of the broader research pipeline lacking published outcomes or remaining in early-stage development.

Depthhow much
21 registered trials
16 completed · 3 with posted results · 5 recruiting / active · combined n=1095
Breadthhow many areas
9 indications mapped
3 with results · 5 thin / exploratory · 1 animal-only · 4 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
3 blinded with results · AE rows aggregated from 3 trials · 10 linked publications on registered trials
Breadth and depth23 rows captured
Human
direct clinical signal
22
Animal
translational support
1
In vitro
mechanistic support
0
HighMediumLow

Anecdotal efficacy

Survodutide side effects

Clinical research side effects

Anecdotal side effects

Price

Full buying guide →
1
Uther
unknown
100 mg×10
$230.00
$2.3/mg
2
High Purity Peptides
Hong Kong
100 mg×10
$300.00
$3/mg
3
Mrbeetoe
--
50 mg
$150.00
$3/mg
4
Chimera Peptides
CN
100 mg×10
$339.00
$3.39/mg
5
Bulk Peptide Supply
unknown
100 mg×10
$350.00
$3.5/mg
6
HKRoids
Hong Kong
100 mg×10
$409.00
$4.09/mg

price offers can be sorted by column · 8 out-of-stock offers not shown

1-6 of 43

SURVODUTIDE dosing & protocol

How SURVODUTIDE is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 17
Typical dose
2.4 mg300 µg – 3.6 mg
typical
0
2 mg
4 mg
6 mg
8 mg
10 mg
distribution of 6 reported doses · darker = more
Frequency
weekly
Route
subQ

In the research trials, SURVODUTIDE was given subcutaneously once weekly, with doses ranging from 0.3 mg to 3.6 mg and a typical dose of 2.4 mg per injection.

17 sources
Clinician practice
Doctor & published-protocol guidance · n = 2
Typical dose
6 mg
typical
0
2 mg
4 mg
6 mg
8 mg
10 mg
distribution of 2 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
daily
Route
subQ

In clinician reports, 6 mg subcutaneously has been used either daily or weekly, with no cycling regimen reported at this time.

2 sources
Anecdotal
Community-reported real-world use · n = 12
Typical dose
10 mg300 µg – 10 mg
typical
0
2 mg
4 mg
6 mg
8 mg
10 mg
distribution of 16 reported doses · darker = more
Frequency
unspecified
Route
subQ

Community reports show Survodutide doses from 300 µg up to 10 mg given subcutaneously, with 10 mg being the most frequently cited amount.

12 sources

Related peptides

SemaglutideTirzepatideRetatrutideAOD-9604CagrilintideOrforglipronLiraglutideExenatideTesamorelinEloralintideTesofensineMazdutide